CD8A and cancer: To evaluate the presence of pre-existing SVX-specific T-cell precursors in cancer patients, PBMCs (including both CD4+ and CD8+ T cells) of cancer patients (and healthy donors as controls) were cultured with the three SVX peptides for 1 week (short-term in vitro culture).